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Abstract
Background: Geranylgeranyltransferase I (GGTase I) has emerged as a cancer therapeutic target. Accordingly, small
molecules that inhibit GGTase I have been developed and exhibit encouraging anticancer activity in preclinical
studies. However, their underlying anticancer mechanisms remain unclear. Here we have demonstrated a novel
mechanism by which GGTase I inhibition modulates apoptosis.
Results: The GGTase I inhibitor GGTI-298 induced apoptosis and augmented tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. GGTI-298 induced DR4 and DR5
expression and reduced c-FLIP levels. Enforced c-FLIP expression or DR5 knockdown attenuated apoptosis induced
by GGTI-298 and TRAIL combination. Surprisingly, DR4 knockdown sensitized cancer cells to GGTI298/TRAIL-induced
apoptosis. The combination of GGTI-298 and TRAIL was more effective than each single agent in decreasing the
levels of IBa and p-Akt, implying that GGTI298/TRAIL activates NF-B and inhibits Akt. Interestingly, knockdown of
DR5, but not DR4, prevented GGTI298/TRAIL-induced IBa and p-Akt reduction, suggesting that DR5 mediates
reduction of IBa and p-Akt induced by GGTI298/TRAIL. In contrast, DR4 knockdown further facilitated GGTI298/
TRAIL-induced p-Akt reduction.
Conclusions: Both DR5 induction and c-FLIP downregulation contribute to GGTI-298-mediated augmentation of
TRAIL-induced apoptosis. Moreover, DR4 appears to play an opposite role to DR5 in regulation of GGTI/TRAIL-
induced apoptotic signaling.
Background
There are two major apoptotic signaling pathways: the
intrinsic mitochondria-mediated pathway and the extrin-
sic death receptor-induced pathway, and these pathways
are linked by the truncated proapoptotic protein Bid [1].
The extrinsic apoptotic pathway is negatively regulated
primarily by the cellular FLICE-inhibitory protein (c-
FLIP), including both long (FLIPL)a n ds h o r t( F L I P S)
forms, through inhibition of caspase-8 activation,
whereas the intrinsic apoptotic pathway is negatively
regulated by multiple proteins including survivin [2].
The tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) binds to its receptors: death receptor 4
(DR4, also named TRAIL-R1) and death receptor 5
(DR5, also named TRAIL-R2) to activate the extrinsic
apoptotic pathway [3]. Recently TRAIL has received
much attention because it preferentially induces apopto-
sis in transformed or malignant cells, demonstrating
potential as a tumor-selective apoptosis-inducing cyto-
kine for cancer therapy [3]. Currently TRAIL is being
tested in phase I clinical trials. However, some cancer
cells are resistant to TRAIL [4,5]. Thus agents that can
sensitize cancer cells to TRAIL are useful to enhance
the efficacy of TRAIL-based cancer therapy or to over-
come TRAIL-resistance [6].
Protein geranylgeranyltransferase type I (GGTase I)
is responsible for the posttranslational modification of
CAAX motif-containing proteins such as K-Ras, N-Ras,
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involved in cell transformation, tumor development
and metastasis [7,8]. Thus, GGTase I has been consid-
ered a good cancer therapeutic target and thus great
efforts have been made to develop GGTase I inhibitors
as anticancer drugs [7,9]. Earlier studies using the
GGTase I inhibitor, GGTI-287, showed K-Ras, a sub-
strate for both GGTase I and farnesyltransferase
(FTase), was particularly sensitive to GGTase I inhibi-
tion [10]. This finding was further supported by a
genetic approach which has shown that GGTase I defi-
ciency reduces tumor formation and improves survival
in mice with K-Ras-induced lung cancer [11], thus
further supporting the importance of GGTase I inhibi-
tion as a useful strategy to treat cancer, particularly K-
Ras-induced cancer.
It has been documented that GGTase I inhibitors
induce apoptosis in human cancer cells [12-16]. How-
ever, the underlying mechanisms are largely unknown
although it appears to be associated with inhibition of
Akt and downregulation of survivin and Mcl-1 [13,14].
The present study focused on examining the effects of
the GGTase I inhibitor GGTI-298, as well as GGTI-
DU40, on induction of apoptosis, particularly induced
by TRAIL, in human non-small cell lung cancer
(NSCLC) cells and on understanding underlying
mechanisms.
Methods
Reagents
GGTI-298 was purchased from Sigma Chemical Co. (St.
Louis, MO). GGTI-DU40 and its inactive analog SN-
DU40 were described previously [17]. These agents were
dissolved in DMSO at the concentration of 20 mM, and
aliquots were stored at -80°C. Stock solutions were
diluted to the appropriate concentrations with growth
medium immediately before use. The soluble recombi-
nant human TRAIL was purchased from PeproTech,
Inc. (Rocky Hill, NJ). Rabbit polyclonal anti-DR5 anti-
body was purchased from ProSci Inc (Poway, CA).
Mouse monoclonal anti-DR4 antibody (B-N28) was pur-
chased from Diaclone (Stamford, CT). Mouse monoclo-
nal anti-FLIP antibody (NF6) was purchased from Alexis
Biochemicals (San Diego, CA). Mouse monoclonal anti-
caspase-3 antibody was purchased from Imgenex (San
Diego, CA). Rabbit polyclonal anti-caspase-8, anti-cas-
pase-9, anti-PARP, anti-survivin and anti-phospho-Akt
(p-Akt; Ser473) antibodies, and monoclonal anti-IBa,
and anti-phospho-IBa (p-IBa; Ser32/36) antibodies
were purchased from Cell Signaling Technology, Inc.
( B e v e r l y ,M A ) .G o a tp o l y c l o n a la n t i - R a p 1 A( C - 1 7 ;s c -
1842) and rabbit polyclonal anti-RhoB (119) antibodies
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Rabbit polyclonal anti-b-actin and anti-tubu-
lin antibodies were purchased from Sigma Chemical Co.
Cell Lines and Cell Culture
Human NSCLC cell lines used in this study were pur-
chased from the American Type Culture Collection
(Manassas, VA). The stable transfectants H157-Lac Z-
5, H157-FLIPS-1, A549-Lac Z-9 and A549-FLIPS-8
were described previously [18,19]. The NF-Br e p o r t e r
stable cell line A549 with chromosomal integration of
a luciferase reporter construct regulated by 6 copies of
the NF-B response element was purchased from
Panomics, Inc (Fremont, CA). These cell lines were
cultured in RPMI 1640 containing 5% fetal bovine
serum at 37°C in a humidified atmosphere of 5% CO2
and 95% air.
Cell Survival Assay
Cells were seeded in 96-well cell culture plates and trea-
ted the next day with the agents indicated. The viable
cell number was determined using the sulforhodamine B
assay, as previously described [20].
Detection of Apoptosis
Apoptosis was evaluated by Annexin V staining using
Annexin V-PE apoptosis detection kit purchased from
BD Biosciences (San Jose, CA) following the manufac-
turer’s instructions. Caspase activation was also detected
by Western blotting (as described below) as an addi-
tional indicator of apoptosis.
Western Blot Analysis
Whole-cell protein lysates were prepared and analyzed
by Western blotting as described previously [21,22].
Luciferase Activity Assay
The given cells were lysed with Reporter Lysis Buffer
(Promega; Madison, WI) and subjected to luciferase
activity assay using Luciferase Assay System (Promega)
in a luminometer. Relative luciferase activity was nor-
malized to protein content.
Gene Silencing Using Small Interfering RNA (siRNA)
The non-silencing control, DR4 (#1), DR5 and c-FLIP
siRNA duplexes were described previously [22-24].
Additional DR4 siRNAs that target different regions of
DR4 gene were also used in this study. DR4 #2 and DR4
#3 siRNAs target 5’-AACGAGATTCTGAGCAACGCA-
3’ (954-974) and 5’-AATGAGATCGATGTGGTCAGA-
3’ (1239-1259), respectively. RhoB siRNA (sc-29475) was
purchased from Santa Cruz Biotechnology. Transfection
of these siRNA duplexes were conducted in 6-well or
96-well plates using the HiPerFect transfection reagent
(Qiagen, Valencia CA) following the manufacturer’s
manual. Gene silencing effects, caspase activation and
other protein expression were evaluated by Western
blot analysis, whereas cell survival and apoptosis were
measured by the SRB assay and Annexin V staining,
respectively, as described above.
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GGTI-298 Induces Apoptosis of Human NSCLC Cells
GGTI-298 was previously shown to induce G1 arrest
and apoptosis in A549 lung cancer cells [15]. In this
study, we compared the effects of GGTI-298 on cell
growth and induction of apoptosis in a panel of human
NSCLC cell lines. After a 3-day exposure, GGTI-298
exhibited concentration-dependent effects on decreasing
the cell numbers of 6 NSCLC cell lines tested, with
IC50s ranging between 2 to 10 μM, indicating that
GGTI-298 effectively inhibits the growth of human
NSCLC cells. Among these cell lines, the H226 cell line
was the least sensitive to GGTI-298 (Fig. 1A). By
Annexin V staining, we detected an increase in the
number of apoptotic cells as well as necrotic cells in the
four tested cell lines (i.e., A549, Calu-1, H157 and
H226) exposed to GGTI-298 for 48 h, demonstrating
that GGTI-298 induces cell death, particularly apoptotic
cell death. Similarly, we detected the least apoptotic
cells in H226 cells treated with GGTI-298, indicating
that H226 cells were less sensitive to GGTI-298-induced
apoptosis (Fig. 1B). In agreement with previous reports,
we found that GGTI-298 also induced G1 arrest in
these NSCLC cell lines (data not shown).
GGTI-298 Cooperates with TRAIL to Augment Apoptosis
in Human NSCLC Cells
GGTase I, like FTase, is a cytosolic heterodimer consist-
ing of a specific b subunit and a common a subunit,
which is used in FTase heterodimers as well [7]. We
previously showed that FTase inhibitors cooperate with
TRAIL to augment apoptosis [25,26]. The present study
determined whether GGTI-298 possesses similar activ-
ity. To this end, we examined the effects of GGTI-298
combined with TRAIL on the induction of apoptosis in
a panel of human NSCLC cells. As presented in Fig. 1C,
the GGTI-298 and TRAIL combination was more
potent than each single agent alone in decreasing the
survival of the four NSCLC cell lines tested, A549, Calu-
1, H157 and H226. Among these cell lines, H226 was
the least sensitive cell line responding to the combina-
tion treatment. Moreover, we directly detected apoptosis
in cells exposed to TRAIL in the absence and presence
of GGTI-298. Compared with TRAIL or GGTI-298
alone, the combination of GGTI-298 and TRAIL
induced more apoptosis in both Calu-1 and A549 cells
(Fig. 1D). For example, in A549 cells, TRAIL alone at 5
ng/ml and 20 ng/ml caused approximately 5% and 30%
apoptosis, respectively, and GGTI-298 alone at 15 μM
induced only 2% apoptosis; however, the combination of
GGTI-298 with 5 ng/ml or 20 ng/ml TRAIL induced
more than 40% or 50% apoptosis, respectively (Fig. 1D).
Collectively, these results indicate that GGTI-298
cooperates with TRAIL to augment induction of apopto-
sis in human NSCLC cells.
GGTI-298 Modulates the Expression of DR4, DR5 and c-
FLIP
Given that GGTI-298 cooperates with TRAIL to aug-
ment induction of apoptosis, we were interested in
examining the underlying mechanisms. To this end, we
determined whether GGTI-298 modulated the expres-
sion of DR4, DR5 and c-FLIP, which are key compo-
nents in the TRAIL-mediated apoptotic pathway [27].
We found that GGTI-298 increased the expression of
DR4 and DR5 while reducing the levels of c-FLIP, parti-
cularly the short form of c-FLIP (FLIPS) in A549, Calu-1
and H157 cells which are sensitive to GGTI-298 or the
combination of GGTI-298 and TRAIL. However, GGTI-
298 did not reduce c-FLIP levels or increased DR5
expression although it did increase DR4 expression in
H226 cells which are less sensitive to undergo apoptosis
by GGTI-298 or GGTI-298 plus TRAIL (Fig. 2A). In
A549 cells, GGTI-298 modulated the levels of DR4,
DR5 and FLIPS in both concentration- and time-depen-
dent manners. GGTI-298 at even 5 μM increased
expression of DR4 and DR5 and decreased FLIPS levels
(Fig. 2B). Downregulation of FLIPS occurred at 3 h post
GGTI-298 treatment; however, induction of DR4 or
DR5 was detected after or at 6 h post GGTI-298 treat-
ment (Fig. 2C), indicating that FLIPS downregulation
occurs earlier than DR4 or DR5 induction in cells
exposed to GGTI-298. We noted that FLIPL levels were
r e d u c e da te a r l yt i m e s( e . g . ,3ha n d6h )b u tn o ta tl a t e
times (e.g., 12 and 24 h) (Fig. 2C). In H226 cells, GGTI-
298 had minimal effects on upreuglating DR5 and redu-
cing c-FLIP levels over the test time period from 3 h to
24 h (data not shown).
GGTI-298 was previously shown to inhibit Akt phos-
phorylation and downregulate survivin levels, which con-
tribute to GGTI-induced apoptosis in ovarian cancer cells
[14]. We also determined whether GGTI-298 exerted
similar effects in human NSCLC cells. GGTI-298 indeed
decreased the levels of p-Akt and survivin in A549 cells,
w h i c ho c c u r r e de v e na t3hp o s tG G T I - 2 9 8t r e a t m e n t
(Figs. 2A-C). These effects appeared cell line-dependent
because GGTI-298 did not reduce the levels of p-Akt and
survivin in the other three cell lines (i.e., Calu-1, H157 and
H226 cells) (Fig. 2A). In fact, GGTI-298 even increased p-
Akt levels in Calu-1 and H226 cells (Fig. 2A).
At the tested concentration ranges (5-15 μM), GGTI-
298 inhibited the prenylation of Rap1 as indicated by an
increase in the levels of unprenylated Rap1 (Fig. 2), a
protein known to be modified by GGTase-1, indicating
that GGTI-298 at the tested conditions inhibits protein
geranylgeranylation.
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Page 3 of 15Figure 1 GGTI-298 as a single agent (A and B) or combined with TRAIL (C and D) inhibits the growth (A and C) and induces apoptosis
(B and D) of human NSCLC cells. A and C, The indicted cell lines were seeded in 96-well cell culture plates and treated the next day with the
given concentrations of GGTI-298 (A) or with the given concentrations of GGTI-298 alone, TRAIL alone, and their combinations as indicated (C).
After 3 days (A)o r2 4h( C), cell number was estimated using the SRB assay. Data are the means of four replicate determinations; Bars, ± SDs. B
and D, The indicated cell lines were treated with 15 μM GGTI-298 for 48 h (B) or with the indicated doses of TRAIL alone, 15 μM GGTI-298 alone,
and their respective combinations for 24 h (D). Apoptosis were then determined by Annexin V staining.
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Contributes to DR5 Induction
It is known that RhoB is modified and upregulated by
both FTase and GGTase inhibitors [28]. Given that both
FTase and GGTase inhibitors induce DR5 expression
based on our previous [25,26] and current studies (Fig.
2), we then determined whether RhoB modulation is
involved in DR5 induction by GGTI-298. To this end,
we first examine whether GGTI-298 increases RhoB
expression in our cell systems. In agreement with pre-
vious findings [28], GGTI-298 strongly induced RhoB
upregulation at 6 h post treatment (Fig. 3A). Transfec-
tion of RhoB siRNA abolished RhoB induction by
GGTI-298. Subsequently, GGTI-298 increased DR5
levels by 4.1 fold in control siRNA-transfected cells, but
only by 2.3 fold in RhoB siRNA-trasnfected cells (Fig.
3B), indicating that blockade of RhoB upregulation par-
tially inhibits DR5 induction by GGTI-298. We also
examined DR4 induction and FLIPS reduction in these
cells and found that both DR4 induction and FLIPS
decrease by GGTI-298 were basically same between
control siRNA- and RhoB siRNA-trasnfected cells (Fig.
3B), indicating that Rhob upredulation is not responsible
for GGTI-298-mediated DR4 induction and c-FLIP
downregualtion.
Another GGTase I Inhibitor GGTI-DU40 Exerts Similar
Effects in Modulation of DR4, DR5 and c-FLIP Levels, and
Augmentation of TRAIL-induced Apoptosis
To determine whether other GGTase I inhibitors also
modulate c-FLIP, DR4 and DR5 and augment TRAIL-
induced apoptosis, we compared the effects of another
highly selective GGTase I inhibitor, GGTI-DU40, and
its structural analog, SN-DU40, which has minimal
GGTase I-inhibitory activity [17], on modulation of c-
FLIP, DR4, DR5 and TRAIL-induced apoptosis. Indeed,
we confirmed that GGTI-DU40, but not SN-DU40,
inhibited the prenylation of Rap1 in our cell systems
(Fig. 4A). Compared to SN-DU40, which minimally or
very weakly inhibited the growth of NSCLC cells,
GGTI-DU40 effectively inhibited the growth of NSCLC
cells with IC50so fa r o u n d1 0μMo rl e s s( F i g .4 B ) .
GGTI-DU40 at concentrations of 2.5-10 μMe x e r t e d
concentration-dependent effects on downregulation of
c-FLIP and induction of DR5 expression, whereas SN-
DU40 at 10 μM only minimally or weakly modulated
the levels of c-FLIP and DR5 in both Calu-1 and H157
cells (Fig. 4A). Consistently, GGTI-DU40, but not SN-
DU40, enhanced TRAIL’s effect on decreasing the survi-
val of NSCLC cells in a concentration-dependent man-
ner (Fig. 4C). In addition, GGTI-DU40, but not SN-
Figure 2 GGTI-298 modulates the levels of DR4, DR5, c-FLIP, p-Akt and survivin in human NSCLC cells. A, The given cell lines were
treated with 15 μM GGTI-298 for 16 h. B, A549 cells were treated with the indicated concentrations of GTI-298 for 16 h. C, A549 cells were
treated with 15 μM GGTI-298 for the given times. After the aforementioned treatments, the cells were subjected to preparation of whole-cell
protein lysates and subsequent Western blotting. LE, longer exposure; UP, unprenylated.
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effects on inducing cleavage of caspase-8, caspase-9, cas-
pase-3 and PARP in both A549 and Calu-1 cells (Fig.
4D).
We noted that GGTI-DU40 at concentrations of 2.5
and 5 μM and SN-DU40 at 10 μM increased DR4
expression in Calu-1 cells; however they did not elevate
DR4 levels in H157 cells. GGTI-DU40 at 10 μMe v e n
decreased the levels of DR4 in H157 cells (Fig. 4A).
Nonetheless, these results may suggest that modulation
of DR4 plays a less important role than the modulation
of DR5 and c-FLIP in GGTase I inhibitor-mediated reg-
ulation of apoptosis.
c-FLIP Downregulation is Important for Augmentation of
TRAIL-induced Apoptosis by GGTI-298 and for GGTI-
induced Apoptosis
It is well known that c-FLIP is a major inhibitor of
TRAIL-induced apoptosis [29]. Since GGTI-298 rapidly
downregulates c-FLIP, particularly FLIPS levels, it is
plausible to reason that FLIPS downregulation is critical
for cooperative induction of apoptosis by GGTI-298 and
TRAIL or for induction of apoptosis by GGTI-298. To
test this hypothesis, we examined the impact of FLIPS
overexpression on cell sensitivity to induction of apopto-
sis by GGTI-298 plus TRAIL. In both H157 and A549
cell lines, enforced expression of ectopic FLIPS con-
ferred resistance to the combination of GGTI-298 and
TRAIL both by measuring cell survival (Fig. 5A) and by
detecting apoptotic cells with Annexin V staining (Fig.
5B). For example, GGTI-298 plus TRAIL induced 53%
and 61% apoptosis, respectively, in H157-LacZ-5 and
A549-Lac Z-9 control cell lines, but only 17% and 26%
apoptosis, respectively, in H157-FLIPS-1 and A549-
FLIPS-8 cells (Fig. 5B). Thus, enforced elevation of
FLIPS levels protects cells from apoptosis induced by
the GGTI-298 and TRAIL combination, suggesting that
c-FLIP downregulation is critical for cooperative induc-
tion of apoptosis by the GGTI-298 and TRAIL
combination.
Moreover, we determined whether enforced FLIPS
expression made cells less sensitive to GGTI-298-
induced apoptosis. As shown in Fig. 6, GGTI-298
decreased cell survival more in H157-LacZ-5 than in
H157-FLIPS-1 cells (Fig. 6A). Consistently, GGTI-298
induced more apoptotic cells in H157-LacZ-5 (approxi-
mately 50%) than in H157-FLIPS-1 cells (approximately
20%) (Fig. 6B). These results indicate that enforced
expression of FLIPS confers cell resistance to GGTI-
298-induced apoptosis. H226 cells in which c-FLIP
levels are not reduced by GGTI-298 are not sensitive to
GGTI-induced apoptosis. We speculated that enforced
downregulation of c-FLIP would sensitize the H266 cells
to GGTI-298-induced apoptosis if c-FLIP levels deter-
mine cell sensitivity to GGTI-298-induced apoptosis.
Thus, we reduced c-FLIP levels through siRNA-
mediated gene silencing and then examined cell
response to GGTI-298. As presented in Fig. 6C, trans-
fection of c-FLIP siRNA substantially reduced the levels
of c-FLIP (both FLIPL and FLIPS). GGTI-298 at high
dose of 30 μM reduced the levels of both FLIPL and
FLIPS with moderate effects on cleavage of caspase-8,
caspase-3 and PARP in control siRNA-transfected cells.
However, in c-FLIP siRNA-transfected cells, the effects
of GGTI-298 on cleavage of caspase-8, caspase-3 and
PARP were drastically enhanced when comparing the
levels of the proforms and cleaved forms of these pro-
teins. In agreement, GGTI-298 decreased cell numbers
more effectively in c-FLIP siRNA-transfected cells than
in control siRNA-transfected cells (Fig. 6D). For exam-
ple, c-FLIP silencing alone caused about 20% cell num-
ber decrease and GGTI-298 alone at 10 μMa n d2 0μM
decreased cell number by approximately 40% and 50%,
respectively (in control siRNA-transfected cells).
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Figure 3 RhoB is upregulationed by GGTI-298 (A) and in part
mediates DR5 upregulation by GGTI-298 (B). A, A549 cells were
treated with 15 μM GGTI-298 for the given times and then
subjected to preparation of whole-cell protein lysates and
subsequent Western blotting. B, A549 cells were cultured in a 6-well
plate and the next day transfected with the indicated siRNAs. After
36 h, the cells were treated with 15 μM GGTI-298 for 12 h and then
subjected to preparation of whole-cell protein lysates for Western
blotting. Ctrl, control; LE, longer exposure.
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Figure 5 Enforced expression of ectopic FLIPS attenuates the effects of the GGTI-298 and TRAIL combination on decreasing cell
survival (A) and inducing apoptosis (B). A, The indicated transfectants were seeded in 96-well plates and treated with the indicated
concentrations of GGTI-298 plus 20 ng/ml TRAIL. After 24 h, the cells were subjected to the SRB assay for measurement of cell number. Data are
means of four replicate determinations. Bars, ± SDs. B, The indicated transfectants were treated with DMSO, 15 μM GGTI-298, 20 ng/ml TRAIL,
and the combination of GGTI-298 and TRAIL for 24 h and then subjected to detection of apoptosis by Annexin V staining. GGTI, GGTI-298.
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number by more than 60% and 80%, respectively (in c-
FLIP siRNA-transfected cells) (Fig. 6D), showing an
additive or more than additive effect on decreasing cell
survival. Taken data from Figs. 6C and 6D together, we
s u g g e s tt h a te n f o r c e dd o w n r e gulation of c-FLIP levels
sensitizes cells to GGTI-298-induced apoptosis. Collec-
tively, we suggest that downregulation of c-FLIP is also
important for GGTI-298-induced apoptosis.
GGTI-298 Enhances TRAIL-induced Apoptosis Involving
DR5 Upregulation
Ligation of TRAIL with its death receptors including
DR4 and DR5 is the first step in transducing apoptotic
signaling. Thus, it is reasonable to speculate that upre-
gulation of DR4 and DR5 also contributes to augmenta-
tion of TRAIL-induced apoptosis by GGTI-298. To
prove this, we blocked induction of DR4, DR5 or both
DR4 and DR5 though siRNA-mediated gene silencing
and then determined the impact on GGTI-298 plus
TRAIL-induced apoptosis. As presented in Fig. 7A (left
panel), transfection of either DR4 or DR5 siRNA suc-
cessfully decreased the basal levels and induced levels of
DR4 or DR5 compared to transfection of the control
siRNA. GGTI-298 plus TRAIL induced cleavage of cas-
pase-8, caspase-3 and PARP in cells transfected with the
control siRNA or DR4 siRNA, but only minimally in
cells transfected with DR5 siRNA or both DR4 and DR5
siRNAs. Consistently, Annexin V staining also demon-
strated that the GGTI-298 and TRAIL combination
induced less apoptosis in cells transfected with DR5
siRNA (15%) or both DR4 and DR5 siRNAs (20%) than
in cells transfected with the control (37%) or DR4
siRNA (84%) (Fig. 7A, right panel). We noted that DR4
silencing in fact made cells more sensitive to GGTI-298
plus TRAIL-induced apoptosis. Nonetheless, blockade of
DR5 induction attenuates cooperative induction of
apoptosis by the combination of GGTI-298 and TRAIL.
To further demonstrate the role of DR4 induction in
GGTI-298 plus TRAIL-induced apoptosis, we used two
additional DR4 siRNAs that target different regions of
the DR4 gene. Similarly, both DR4 #2 and DR4 #3
siRNA effectively decreased basal levels of DR4 and
blocked GGTI-298-induced DR4 expression without
affecting DR5 expression (Fig. 7B, left panel). Under
such conditions, GGTI-298 plus TRAIL induced 32%
apoptosis in control siRNA-transfected cells, but 58%
and 62% apoptosis, respectively, in DR4 #2 siRNA-trans-
fected and DR4 #3 siRNA-transfected cells (Fig. 7B,
right panel). These results again indicate that DR4 silen-
cing sensitizes cells to induction of apoptosis by the
combination of GGTI-298 and TRAIL.
The results on silencing of DR4 expression-mediated
sensitization of A549 cells to GGTI-298 plus TRAIL-
induced apoptosis appear surprising. We further
reproduced this finding in the H157 NSCLC cell line, in
which both DR4 and DR5 are induced by GGTI-298. In
agreement with the results in A549 cells, blockade of
GGTI-298-induced DR4 upregulation substantially
enhanced GGTI-298 plus TRAIL-induced PARP clea-
vage and apoptosis (80% vs. 40% apoptosis in DR4
siRNA-transfected cells vs. control siRNA-transfected
cells) (Fig. 7C). Therefore, the sensitization of GGTI-298
plus TRAIL-induced apoptosis by silencing DR4 is not
restricted to only A549 cells.
The Combination of GGTI-298 and TRAIL Facilitates IBa
Degradation and Akt Inhibition
It has been shown that DR4 mediates NF-B activation
while inducing apoptosis although other studies showed
that both DR4 and DR5 activate NF-B [30,31]. Thus, it
is possible that knockdown of DR4 abolishes NF-B
activation, leading to sensitization of DR5-dependent
apoptosis induced by the combination of GGTI298 and
TRAIL. To test this hypothesis, we first determined
whether the GGTI-298 and TRAIL combination aug-
ments NF-B activation by examining IBa phosphory-
lation and degradation. The combination of GGTI-298
and TRAIL rapidly increased IBa phosphorylation
accompanied with reduction of IBa levels at 1 h post
the combination exposure (Fig. 8A, upper panel), indi-
cating that the GGTI-298 and TRAIL combination
induces IBa degradation. The combination was more
potent that either GGTI-298 or TRAIL alone in increas-
ing p-IBa levels and reducing IBa levels (Fig. 8A,
lower panel), indicating that the combination of GGTI-
198 and TRAIL augments IBa degradation. Given that
IBa degradation is often associated with NF-B activa-
tion, we further determined whether the GGTI-298 and
TRAIL combination enhances NF-B activation. As
shown in Fig. 8B, GGTI-298 and TRAIL alone weakly
increased NF-B activity as indicated by measuring NF-
B luciferase activity; however their combination caused
the highest NF-B activity. Thus, the GGTI-298 and
TRAIL combination augments NF-B activity as well.
Akt is another important survival pathway that main-
tain the growth of cancer cells by conferring apoptotic
resistance [32]. Thus, we also looked at the effect of the
GGTI-298 and TRAIL combination on Akt activation.
The combination caused transient increase in p-Akt
levels (e.g., 1 and 2 h) followed by substantial reduction
of p-Akt levels (e.g., 4 h and 8 h) (Fig. 8A). These
results indicate that prolonged exposure of cancer cells
to the combination of GGTI-298 and TRAIL inhibits
Akt phosphorylation.
DR4 and DR5 Play Opposite Roles in Mediating GGTI-298
plus TRAIL-induced IBa Degradation and Akt Inhibition
Moreover, we determined the roles of DR4 and DR5 in
mediating GGTI-298 plus TRAIL-induced IBa degra-
dation and Akt inhibition To this end, we used siRNA
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at their respective impact on IBa degradation and Akt
inhibition. Transfectiono fe i t h e rD R 4o rD R 5s i R N A
substantially reduced the levels of either DR4 or DR5
(Fig. 8C), indicating the successful knockdown of DR4
or DR5. Unexpectedly, knockdown of DR5, but not
DR4, abrogated GGTI-298 plus TRAIL-induced reduc-
tion of both IBa and p-Akt (Fig. 8C), indicating that
the combination of GGTII-298 and TRAIL induces
DR5-dependent IBa degradation and Akt inhibition.
Interestingly, silencing of DR4 even further enhanced
the effects of the GGTI-298 and TRAIL combination on
inhibition of Akt phosphorylation (Fig. 8C), suggesting
that DR4 may play a role in preventing p-Akt downre-
gulation during GGTI-298 plus TRAIL-induced apopto-
sis. Thus, it appears that DR4 and DR5 play opposite
Figure 6 Modulation of c-FLIP levels by enforcing expression of ectopic c-FLIP (A and B) or siRNA-mediated downregulation of c-FLIP
(C and D) regulates cell sensitivity to GGTI-298-induced apoptosis. A and B, The indicated transfectants were treated with the given
concentrations of GGTI-298 (A)o r1 5μM GGTI-298 (B) for 48 h and then subjected to estimation of cell number using the SRB assay (A)o r
detection of apoptosis by Annexin V staining (B). C and D, H226 cells seeded in a 6-well plate (C) or a 96-well (D) plate were transfected with
control (Ctrl) or c-FLIP siRNA. Twenty-four hours later, the cells were exposed to 30 μM( C) or the indicated concentrations (D) of GGTI-298. After
24 h, the cells were subjected to preparation of whole-cell protein lysates and subsequent detection of the indicated proteins using Western
blotting (C) or to estimation of cell number by the SRB assay (D). Data in A and D are means of four replicate determinations. Bars, ± SDs. CF,
cleaved form.
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Page 10 of 15Figure 7 Blockage of DR5 induction abrogates augmented induction of apoptosis by GGTI-298 and TRAIL combination (A), whereas
inhibition of DR4 induction sensitizes cells to GGTI-298 plus TRAIL-induced apoptosis (A -C). A and B, A549 cells were cultured in a 6-well
plate and the next day transfected with the indicated siRNAs twice in a 24 h interval. Twenty four hours after the second transfection, cells were
treated with 15 μM GGTI-298 plus 20 ng/ml TRAIL (A and B, right panel) or 15 μM GGTI-298 only (B, left panel) for 8 h and then subjected to
preparation of whole-cell protein lysates for Western blotting (A and B, left panels) or detection of apoptosis by Annexin V staining (A and B,
right panels). C, H157 cells were cultured in a 6-well plate and the next day transfected with the indicated siRNAs twice in a 24 h interval.
Twenty four hours after transfection, the cells were treated with 15 μM GGTI-298, 20 ng/ml TRAIL or GGTI-298 plus TRAIL. After 8 h (left panel)
and 24 h (right panel), the cells were harvested for preparation of whole-cell protein lysates for Western blotting (left panel) or for detection of
apoptosis by the Annexin V staining (right panel), respectively. Data are means of duplicate experiments; Bars, ± SEs. Ctrl, control; GGTI, GGTI-298;
G + T, GGTI-298 plus TRAIL; CF, cleaved from.
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inhibition.
Discussion
The present study demonstrates that GGTI-298 inhibits
the growth of human NSCLC cells accompanied with
induction of apoptosis in addition to G1 arrest, indicat-
ing that induction of apoptosis in part accounts for
GGTI-298’s growth inhibitory effects in human NSCLC
c e l l s .G G T I - 2 9 8a sas i n g l ea gent moderately induces
apoptosis. However, GGTI-298 when combined with
TRAIL exerted enhanced apoptosis-inducing activity,
indicating that GGTI-298 cooperates with TRAIL to
augment apoptosis. In agreement, another highly selec-
tive GGTase I inhibitor, GGTI-DU40, but not its inac-
tive analog, SN-DU40, exerted similar effects in
augmenting TRAIL-induced apoptosis. To the best of
our knowledge, this is the first report demonstrating
Figure 8 The combination of GGTI-298 and TRAIL augments Akt inhibition, IBa degradation (A) and NF-B activation (B), which are
differentially modulated by DR4 and DR5 (C). A, A549 cells were treated with the combination of 15 μM GGTI-298 and 20 ng/ml TRAIL for
the given times (upper panel) or with DMSO (D), 15 μM GGTI-298 (G) alone, 20 ng/ml TRAIL (T) alone or GGTI-298 and TRAIL combination (G/T)
for 2 h (lower panel). The cells were then subjected to preparation of whole-cell protein lysates and subsequent detection of the indicated
proteins using Western blotting. B, A549 cells stably transfected with NF-B-luc reporter gene were treated with DMSO, 15 μM GGTI-298 alone,
20 ng/ml TRAIL alone or GGTI-298 and TRAIL combination for 3 h. The cells were then lysed for NF-B luciferase assay, which was finally
normalized by protein content. The columns are means of triplicate determinations; Bars, ± SDs. C, A549 cells were cultured in 6-well plates and
the next day transfected with the indicated siRNAs twice in a 48 h interval. Twenty-four hours after the second transfection, the cells were
treated with 15 μM GGTI-298 plus 20 ng/ml TRAIL (G/T) for the indicated time and then subjected to preparation of whole-cell protein lysates
and subsequent detection of the given proteins using Western blotting.
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augment apoptosis in human cancer cells. Given the
recent study that GGTase I deficiency reduces lung
tumor formation [11], our data suggest that GGTase I
inhibitors may be used in combination with TRAIL for
treatment of human lung cancer through facilitating
induction of apoptosis.
A previous report suggested that inhibition of Akt and
subsequent downregulation of survivin are important for
GGTI-298-induced apoptosis in human ovarian cancer
cells [14]. In our study, we observed that GGTI-298
inhibited Akt phosphorylation and downregulated survi-
vin levels primarily in A549 cells, but not in other tested
NSCLC cell lines (e.g., Calu-1, H157 and H226), indicat-
ing a cell line-specific modulation of Akt and survivin.
In Calu-1 cells, GGTI-298 even increased p-Akt levels.
Since Calu-1 and H157 cells were also sensitive to
induction of apoptosis by either GGTI-298 alone or
GGTI-298 plus TRAIL, inhibition of Akt and survivin is
unlikely to be a common mechanism for GGTI-298- or
GGTI-298 plus TRAIL-induced apoptosis although they
may play roles in individual cell lines (e.g., A549). Cur-
rently, we do not know why GGTI-298 decreases Akt
phosphorylation in some cells lines (e.g., A549), but
increases Akt phosphorylation in others (e.g., Calu-1).
Similar phenomenon was also documented from studies
on FTase inhibitors. Whereas FTase inhibitors decrease
Akt phoshoporylation in some cells [33,34], we pre-
viously reported that the FTase inhibitor SCH66336
increases Akt phosphorylation in some human lung can-
cer cell lines [35].
Importantly, we found that GGTI-298 apparently
downregulated the levels of c-FLIP, particularly FLIPS
and induced the expression of DR4 and DR5, primarily
in GGTI-sensitive cell lines (e.g., A549, Calu-1 and
H157), suggesting an association between modulation of
these proteins and cell sensitivity to GGTI-298 or
GGTI-298 plus TRAIL. We noted that downregulation
of c-FLIP preceded induction of DR4 and DR5, implying
that c-FLIP downregulation may play a critical role in
mediating GGTI-298-induced apoptosis and sensitiza-
tion of TRAIL-induced apoptosis. Indeed, we found that
enforced expression of ectopic FLIPS reduced cell sensi-
tivity to GGTI-298-induced apoptosis, whereas siRNA-
mediated silencing of c-FLIP further increased cell sensi-
tivity to GGTI-298 (Fig. 6). Similarly, enforced expres-
sion of ectopic FLIPS also protected cells from GGTI-
2 9 8p l u sT R A I L - i n d u c e da p o p t o s i s( F i g .5 ) .T h u s ,w e
conclude that c-FLIP, particularly FLIPS, downregulation
plays a crucial role in mediating apoptosis induced by
either GGTI-298 or GGTI-298 combined with TRAIL.
Both DR4 and DR5 are receptors for TRAIL and can
transduce apoptotic signaling upon binding to TRAIL.
Interestingly, we found that silencing of DR5, but not
DR4, abrogated cooperative induction of apoptosis by
the combination of GGTI-298 and TRAIL (Fig. 7). Sur-
prisingly, silencing of DR4 even sensitized cells to apop-
tosis induced by GGTI-298 plus TRAIL as we
demonstrated using three DR4 siRNAs targeting differ-
ent regions of the DR4 gene; however, this sensitization
did not occur in cells where both DR4 and DR5 expres-
sion were silenced (Fig. 7). Taken together, these results
indicate that DR5 induction is also critical for coopera-
tive induction of apoptosis by the combination of
GGTI-298 and TRAIL.
In this study, it appears that DR4 plays an antagonistic
role in GGTI-298 plus TRAIL-induced apoptosis. Given
that both DR4 and DR5 can mediate the TRAIL-
induced NF-B survival signaling pathway while initiat-
ing death signaling [30,31], it is possible that DR4 may
be the major receptor that mediated TRAIL-induced
NF-B activation during TRAIL-induced apoptosis.
Hence, silencing of DR4 would prevent NF-B activa-
tion and enhance GGTI-298 plus TRAIL-induced apop-
tosis. Indeed, the GGTI-298 and TRAIL combination
augmented IBa phosphorylation, IBa degradation and
subsequent NF-B activity (Fig. 8). Unexpectedly,
knockdown of DR5, but not DR4, abrogated GGTI-298
plus TRAIL-induced IBa degradation. Thus, the
GGTI-298 and TRAIL combination induces a DR5-
dependent IBa degradation or NF-B activation.
Accordingly, we concluded that DR4 is unlikely to
antagonize GGTI-298 plus TRAIL-induced apoptosis
through activation of NF-B.
Akt activation is often associated with apoptosis resis-
tance [36]. In this study, we also found that the combi-
nation of GGTI-298 and TRAIL inhibited Akt
phosphorylation. Interestingly, respective knockdown of
DR4 and DR5 generated opposite results on GGTI-298
plus TRAIL-induced p-Akt reduction; i.e., knockdown of
DR5 inhibited p-Akt reduction in cells exposed to the
combination of GGTI-298 and TRAIL, whereas knock-
down of DR4 enhanced the ability of the GGTI-298 and
TRAIL combination to decrease p-Akt levels (Fig. 8C).
Thus, the GGTI-298 and TRAIL combination induces a
D R 5 - d e p e n d e n tA k ti n h i b i t i o n .H e r ei ts e e m st h a tD R 4
may play an opposite role to DR5 in positively regulat-
ing Akt activity. Hence, it is possible that DR4 may
mediate Akt activation, at least in part leading to cell
resistance to GGTI-298 plus TRAIL-induced apoptosis.
To the best of our knowledge, this is the first study to
show the regulation of Akt activity by the TRAIL death
receptors.
The finding on the opposite roles of DR4 and DR5 in
regulation of GGTI-198/TRAIL-induced apoptosis is
intriguing. However, the underlying molecular mechan-
ism(s) have not been elucidated. It is possible that DR5
and DR4 can form a heterodimer, which is less active
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antagonist of DR5 homodimers. Knockdown of DR4 will
favor DR5 homodimer formation while reducing the
DR5/DR4 heterodimer formation, leading to sensitiza-
tion of cells to GGTI-298/TRAIL-induced apoptosis.
Nonetheless, our findings warrant further study in this
direction.
Both GGTase I and FTase are cytosolic heterodimers
that share a common a subunit but use different b sub-
units and are all involved in prenylation of CAAX pro-
teins [7]. Our previous study showed that the FTase
inhibitors SCH66336 and R115777 upregulate DR5
expression and augment TRAIL-induced apoptosis
[25,26]. The current study further shows that the
GGTase I inhibitor GGTI-298 exerts similar effects.
Therefore, future studies should address whether there
is a relationship between inhibition of protein prenyla-
tion and modulation of DR5 and c-FLIP. In this study,
we have shown that GGTI-DU40, but not SN-DU40,
exhibits identical results as GGTI-298 in modulation of
c-FLIP levels, DR5 expression and TRAIL-induced apop-
tosis. Both GGTI-298 and GGTI-DU40 have similar
GGTase I-inhibitory activity; however they possess dis-
tinct chemical structures [17,37]. All of these suggest a
possible link between inhibition of protein geranylgera-
nylation and modulation of DR5 and c-FLIP.
Given that FTase and GGTase I inhibitors affect dif-
ferent set of proteins [8], the question is why both types
of inhibitors exert similar effects on DR5 upregulation.
One possible is that both FTase and GGTase I inhibitors
affect a common protein or pathway, leading to DR5
upregulation. In this study, we investigated the possible
role of RhoB in GGTI-298-induced DR5 upregulation
since RhoB is modified and regulated by both farnesyla-
tion and geranylgeranylation [28]. We found that GGTI-
298 increases RhoB expression (Fig. 3A), which was par-
alleled with DR5 induction (Fig. 2C). Moreover, siRNA-
mediated blockade of RhoB upregulation partially inhib-
ited DR5 induction by GGTI-298 (Fig. 3B). These results
suggest that RhoB in part mediates DR5 induction by
GGTI-298. Because RhoB siRNA transfection completely
blocked RhoB upregulation in our study, but failed to
abolish GGTI-298’s ability to increase DR5 expression
(Fig. 3B), other mechanisms may also account for
GGTI-298-induced DR5 upregulation and need to be
studied further.
Conclusions
The current work focuses on addressing how inhibition
of GGTase I cooperates with TRAIL to augment induc-
tion of apoptosis. In this regard, both c-FLIP downre-
gualtion and DR5 induction are important events that
mediate augmentation of TRAIL-induced apoptosis by
GGTI-298. The unexpected finding on the antagonistic
role of DR4 induction in regulation of GGTI-298/
TRAIL-induced apoptosis is of interest and needs to be
further explored.
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